Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;35(8):e14386.
doi: 10.1111/ctr.14386. Epub 2021 Jun 27.

Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation

Madeline R Hudson  1 , Allyssa R Webb  1 , Angela Tong Logan  1 , Andrew Silverman  1 , Andrew J Brueckner  1
Affiliations

Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation

Madeline R Hudson et al. Clin Transplant. 2021 Aug.

Abstract

The use of allografts from hepatitis C virus (HCV) Nucleic Acid Testing (NAT)+ donors into HCV NAT- recipients has been reported to be efficacious in a handful of studies. However, these studies have not reflected real-world practice where the initiation of direct-acting antivirals (DAA) is dependent on insurance coverage. A single-center, retrospective chart review of HCV NAT- recipients who underwent solid organ transplantation (SOT) from a HCV NAT+ donor between April 1, 2019 and May 27, 2020 was conducted. Sixty-one HCV NAT- patients underwent SOT with a HCV NAT+ organ, with 59 transplant recipients included for evaluation: 22 kidney (KT), 18 liver (LiT), 10 heart (HT), nine lung (LuT). HCV transmission occurred in 100% of recipients. Average time to DAA initiation was POD 46.3 ± 25 days. SVR12 was achieved in 98% (56/57; two patients ineligible for analysis). Treatment failure occurred in one LuT on glecaprevir/pibrentasvir with P32del and Q80K mutations. No patients developed fibrosing cholestatic hepatitis. Two patients died, secondary to anastomotic complication (LuT) and pulmonary embolism (HT). Clinically significant rejection was diagnosed and treated in two HT (one patient with ACR2 and one with ACR2/pAMR2) and one LiT (RAI 5/9). Six patients (10.2%) had documented adverse effects attributed to DAA therapy, primarily gastrointestinal.

Keywords: antiviral; donor-derived infections; hepatitis C; side effects.

PubMed Disclaimer

References

REFERENCES

    1. National Data. Organ Procurement and Transplantation Network. https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/ Published November 26, 2020. Accessed November 26, 2020.
    1. Blumberg EA. Organs from hepatitis C virus-positive donors. N Engl J Med. 2019;380(17):1669-1670.
    1. Levitsky J, Formica RN, Bloom RD, et al. The American society of transplantation consensus conference on the use of hepatitis c viremic donors in solid organ transplantation. Am J Transplant. 2017;17(11):2790-2802.
    1. Treatment of HCV-Uninfected Transplant Recipients Receiving Organs From HCV-Viremic Donors. Hcvguidelines.org. https://www.hcvguidelines.org/unique-populations/organs-from-hcv-viremic... Published August 27, 2020. Accessed November 25, 2020.
    1. Ting PS, Hamilton JP, Gurakar A, et al. Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients. Transpl Infect Dis. 2019;21(6):e13194.

MeSH terms

LinkOut - more resources